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Poster Session II S283The propensity towards clonal evolution may play a key role in de-
termining which patients should be evaluated for transplant earlier
in their disease course.
Summary of metaphase and interphase cytogenetic abnor-
malities
# Abnormalities Transplant No Remission p-value0 6 5
1 4 5
2 12 2
3 1 3
4 3 1
5 or more 8 15 0.03
Cytogenetics
trisomy 12 4 5
del13q 13 19
del11q 8 8
del17 p 14 17 0.197336
FASTER LYMPHOCYTE RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) PREDICTS FOR DECREASED NON-
RELAPSE MORTALITY (NRM) IN ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL)
Yuen, C.H., Saliba, R.M., Andersson, B.S., Shpall, E., Popat, U.R.,
Qazilbash, M.H., Hosing, C., de Lima, M.J., Giralt, S.A.,
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Allogeneic HCT remains an effective means of long-term disease
control in adult ALL, but highNRMwithHCT in these heavily pre-
treated patients (pts) limits overall survival (OS). We looked at pre-
dictors for NRM and OS in pts who had received allogeneic HCT
for intermediate or high risk ALL from 2005 through 2009 at MD
Anderson Cancer Center. 65 pts with median age 32 years (range
18-62) with ALL in remission (CR15 29, CR25 19, greater than
CR25 5) or relapse (n5 5) were identified. Pts received a matched
related (n5 37) or matched unrelated (n5 28) peripheral blood
(n5 50) or bonemarrow (n5 15) T-cell replete transplant following
myeloablative conditioning (Busulfan130 mg/m24/Melpha-
lan70 mg/m22, n5 42; TBI12 Gy/Etoposide 60 mg/kg n5 23).
All patients received tacrolimus and mini-dose methotrexate for
GVHD prophylaxis; unrelated donors additionally received anti-
thymocyte globulin. OS and NRM rates at 2 years were 47% and
32%, respectively, with median follow-up after HCT of 18 months.
Age, disease stage at time of HCT, cytogenetic risk, donor type, cell
source, conditioning regimen, and absolute lymphocyte count on
day 21 (D21ALC) and day 30 (D30ALC) post HCT were evaluated
in a univariate analysis with regards to impact onNRMandOS using
the Cox proportional hazards model. All outcomes were estimated in
landmark analysis starting on day 21 or day 30 as indicated by ALC.
Age .45 years was associated with increased NRM and worse out-
come (HR 4.5, 95%CI 1.1-11.7, p5 0.002 for NRM; HR 2.3,
95%CI 1.1-4.9, p5 0.02 for OS). Early disease (CR1 or CR 2 vs ad-
vanced disease) was associated with decreased NRM and better out-
come (HR 0.4, 95% CI 0.1-0.9, p5 0.04 for NRM; HR 0.3, 95%CI
0.2-0.7, p5 0.003 for OS). Median D21ALC was 300/uL. D21ALC
.300/uL was associated with decreased NRM and better outcome
(HR 0.4, 95%CI 0.1-0.9, p5 0.035 for NRM; HR 0.6, 95%CI
0.3-1.2, p5 0.1 for OS). D30ALC greater than median level 650/
uLwas not associated with better outcome.When analyzed by donor
type, faster ALC recovery was significantly associated with better
outcome in unrelated HCT vs related HCT (p5 .035 vs. p5 0.2).
Further, no associationwas noted betweenALC recovery and disease
stage or age. Small sample size prohibited multivariate analysis. An
association between ALC recovery and HCT outcome has been pre-
viously reported for adult ALL, although this is the first report for
such an association following matched unrelated HCT. A larger
study is needed to confirm these findings.337
BUSULFAN-BASED REDUCED INTENSITY CONDITIONING REGIMEN (RIC)
FOR LYMPHOID MALIGNANCIES
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Witowski, S.1, Abboud, C.1, Uy, G.1, Westervelt, P.1, Dipersio, J.1,
Vij, R.1 1Washington University School of Medicine, St. Louis, MO;
2Washington University School of Medicine, St Louis, MO
Introduction:Though busulfan (Bu) based RIC are popular for my-
eloid malignancies there is a paucity of data on Bu- based RIC for
lymphoid neoplasms. We therefore conducted a single institution
retrospective analysis of a large patient cohort allografted using:
Bu/Fludarabine (Flu) +/- Thymoglobulin (Thymo) RIC regimens
for lymphoid malignancy.
Methods: 62 patients (pts) underwent RIC for lymphoid malignan-
cies between 2004 and 2008 using Bu 0.8 mg/kg q6 hrs 8 doses d-4
d-3, Flu 30 mg/m2 IV d -7 to -3, +/- Thymo 2 mg/kg 4 d-4 to d-1.
Graft versus host disease (GVHD) prophylaxis was tacrolimus (FK)/
methotrexate(Mtx)/mycophenolate(MMF) in 41 pts (65%), FK/Mtx
in 20 pts (32%), cyclosporine/MTx/MMF in 2 pt (3%).
Demographics: Median age 53 (range 20-65) yrs; males 39 (63%)
females 23 (37%); CLL/SLL 21 (34%), non-Hodgkins lymphoma
32 (52%)Hodgkins lymphoma 9 (14%); therapies prior to transplant
4 (range 0-13); Bu/Flu17 pts (27%), Bu/Flu/Thymo 45 pts (73%);
prior radiation therapy (XRT) 45 pts (73%), prior autologous stem
cell transplant (ASCT) 27 pts (30%); median comorbidity index
score (CI) 1 (range 0-5).
Results: After median F/U of 14 mo (0.4-48), Kaplan-Meier esti-
mates of median overall survival (OS) and progression-free survival
(PFS) were 18.3 mo and 9.8 mo, respectively. 2-yr OS was 49.6%,
and the PFSwas 47.7%. 100 day, 1 year, 2 year non-relapsemortality
(NRM) was 8%, 31%, and 35%, respectively.We performed univar-
iate (Table 1) and multivariate analyses for OS, PFS, and NRM. On
multivariate analysis, prior XRT, high CI score, and\PR post
transplant had adverse effects on OS (p5 0.0145, 0.002, 0.0065, re-
spectively); prior XRT and\PR post transplant adverse effects on
PFS (p5 0.0148, p\0.001); and high CI score adverse effects on
NRM (p5 0.0324).
Conclusion: This represents the largest single institution experi-
ence using Bu/Flu +/- Thymo in lymphoid malignancies. We dem-
onstrate prompt, durable engraftment and relatively low NRM.
Prior XRT, CI score, and transplant response predicted for OS;
prior XRT and transplant response for PFS; CI score for NRM.
Table 1. Univariate Analyses
OS-2 years p-value PFS-2 years p-valueAge
\55 56% 0.23 45% 0.74
./5 55 40% 37%Diagnosis
CLL/SLL 52% 0.57 52% 0.41
Non Hodgkins 46% 43%
Hodgkins 64% 13%# lines of chemotherapy
\4 62% 0.61 46% 0.25
./5 4 41% 38%Prior Auto
Yes 55% 0.13 53% 0.08
No 42% 25%Donor Type
Related 47% 0.65 32% 0.39
Unrelated 52% 49%Prior Radiation
Yes 62% 0.008 54% 0.003
No 31% 23%Response to Transplant
CR or PR 62% \0.0001 53% \0.0001
Stable or Prog Disease 20% 15%CI Score
Low 58% 0.01 48% 0.04
Intermediate 54% 45%
High 11% 11%
